Nuvation Bio's IBTROZI Shows Over 4-Year Response in Lung Cancer Study
Event summary
- FDA accepted Nuvation Bio's supplemental New Drug Application for IBTROZI, targeting a January 4, 2027 decision.
- Updated data shows median duration of response of 49.7 months in TKI-naïve patients and 19.4 months in TKI-pretreated patients.
- IBTROZI's safety profile remained consistent with prior reports, with no new signals identified.
- The submission includes additional 10 months of data from TRUST-I and TRUST-II studies as of August 2025.
The big picture
Nuvation Bio's IBTROZI is positioning itself as a potential standard of care for advanced ROS1+ non-small cell lung cancer, backed by long-term clinical data. The FDA's acceptance of the supplemental New Drug Application marks a critical step in solidifying its market position. The company's strategic partnerships in Japan and China, along with its ongoing clinical programs, underscore its commitment to expanding the drug's global reach.
What we're watching
- Regulatory Timeline
- Whether the FDA will approve the supplemental New Drug Application by the target action date of January 4, 2027.
- Market Penetration
- How the updated data will impact IBTROZI's adoption as a standard of care in advanced ROS1+ NSCLC.
- Clinical Data Maturation
- The pace at which additional data from the TRUST-II study will further validate IBTROZI's long-term efficacy.